Review
Nipun Lakshitha de Silva1,
Hasitha Damayanthi2,
Anoja Chamarie Rajapakse3,
Chaturaka Rodrigo1 and
Senaka Rajapakse1*
For all author emails, please
log on.
Allergy, Asthma & Clinical Immunology 2014, 10:24 doi:10.1186/1710-1492-10-24
Published: 7 May 2014
Abstract
A significant proportion of patients with chronic urticaria respond inadequately to first line treatment with antihistamines. Leukotreine receptor antagonists (LTRA) are also used for chronic urticaria, although firm recommendations on their use are lacking. We performed a systematic review of randomised trials to determine the role of LTRA in treatment of chronic urticaria. A search of PUBMED, EMBASE, SCOPUS, LILACS, the Cochrane Central Register of Controlled Trials, and the Web of Science for relevant randomized control trials or cross over studies yielded 10 eligible studies. The heterogeneity of trials were high, preventing valid meta-analysis of data. Most trials indicated that LTRA are not superior to placebo or antihistamine therapy, while combination therapy of LTRA and antihistamines appear to be more efficacious compared to antihistamine alone. The side effect profile and tolerability of this group of drugs is acceptable. The use of LTRA as monotherapy cannot be recommended. LTRA are effective add-on therapy to anti-histamines, and their use in patients responding poorly to antihistamines is justifiable. Further well designed randomized controlled trials with clear and standardized outcome measures are needed to determine the role of LTRA in chronic urticaria.
Keywords:
Chronic urticaria; Leukotreine receptor antagonists; Leukotreine; Montelukast; Zafirlukast; Antihistamines
Viewing options
No comments:
Post a Comment